

**DETAILED ACTION**

1. Amendment and response filed by applicants dated Apr. 19, 2010 have been entered and considered carefully.

Claims 1-12 and newly added claims 13-20 are pending.

2. ***Examiner's Amendment***

Authorization for this examiner's amendment was given in a telephone interview with Csaba Henter on July 1, 2010.

Claim 1, line 5, after the term "denotes" delete "O, OH, NH, NH<sup>2</sup>, NR<sup>2</sup>R<sup>3</sup>".

Claim 5, line 3, delete the terms "a neurological disorder" "a memory disorder";

Line 4, delete the term "an eating disorder";

Line 5, delete the term "a sleeping disorder"

Line 6, after *apnoea* delete, "or"

Lines 6-8, delete

"or a method for the prophylaxis of or for combating the consequences of cerebral infarction phenomena stroke or cerebra ischaemia or a method for positively influencing";

Claim 8, line 3, delete the terms "a neurological disorder" "a memory disorder";

Line 5, delete the term "an eating disorder";

Line 6, delete the term "a sleeping disorder"

Line 6, after *apnoea* delete, "or"

Lines 6-8, delete

"or a method for the prophylaxis of or for combating the consequences of cerebral infarction phenomena stroke or cerebra ischaemia or a method for positively influencing";

**3. Reason for Allowance**

The following is an examiner's statement of reasons for allowance:

Applicants have provided an affidavit under 37 CFR 1.132 with factual evidence that the Q is substituted alkyl compounds have 5HT<sub>2</sub> receptor activity. By the examiner's amendment applicants have limited the claims commensurate with the scope provided by the affidavit and corrected the 112 issues of the claims. Claims 1-20 as currently amended are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

**4.** Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celia Chang, Ph. D. whose telephone number is 571-272-0679. The examiner can normally be reached on Monday through Thursday from 8:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet L. Andres, Ph. D., can be reached on 571-272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

*OACS/Chang*  
*July 1, 2010*

*/Celia Chang/*  
*Primary Examiner*  
*Art Unit 1625*